(Q38071321)

28 August 2017

1 reference

title

Toxicological and metabolic considerations for histone deacetylase inhibitors (English)

1 reference

28 August 2017

2

Tamara Vanhaecke

1 reference

28 August 2017

3

Vera Rogiers

1 reference

28 August 2017

Joanna Fraczek

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

4 January 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

441-457

1 reference

Structural Modifications of Histones and their Possible Role in the Regulation of RNA Synthesis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Histone acetylation and chromatin signature in stem cell identity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase 2 study of vorinostat in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Comment on developmental toxicity evaluation on Vorinostat and relationship with HDAC inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Solubilization of vorinostat by cyclodextrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Rational combinations using HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Histone deacetylase inhibitors: emerging mechanisms of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.754011

10.1517/17425255.2013.754011

21 January 2018

Identifiers

DOI

1 reference

release_m7ec2phcd5f3xpejwaa3ke4sja

28 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m7ec2phcd5f3xpejwaa3ke4sja

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference